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Summary The effect of body mass index (BMI) on outcomes after primary percutaneous coro-
nary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI)
is not well known. In patients registered in the Korean Acute Myocardial Infarction Registry
(KAMIR) between November 2005 and November 2007, 3824 STEMI patients who arrived at
hospital within 12 h after onset of chest pain and underwent primary PCI were analyzed, and
divided into four groups according to their BMI: underweight (BMI < 18.5 kg/m2, n = 129); nor-
mal weight (18.5≤BMI < 23.0 kg/m2, n = 1253); overweight (23.0≤BMI < 27.5 kg/m2, n = 1959);
and obese (BMI≥ 27.5 kg/m2, n = 483). In-hospital mortality, revascularization in 1 year, mortal-
ity in 1 year, and overall mortality were compared between groups. Overweight and obese group
were signiﬁcantly younger, had normal left ventricular ejection fraction, and were more likely
to be men with a higher incidence of hypertension, diabetes, and hyperlipidemia. There were
no signiﬁcant differences in symptom-to-door time and door-to-balloon time between groups.
Obese patients had signiﬁcantly lower in-hospital and overall mortalities. Major adverse cardiac
events showed a bimodal pattern. Obese STEMI patients treated with primary PCI were associated
with lower mortality, which may be explained by better use of medical treatment, hemodynamic
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(SD). We used Chi-square tests for linear-by-linear associa-
tion, or one-way ANOVA for statistical comparisons of clinicalstability, and younger age.
© 2009 Japanese College of C
Introduction
Generally, overweight and obesity are associated with an
increased risk of developing cardiovascular disease [1,2].
Furthermore, obesity is associated with endothelial dys-
function, insulin resistance, and inﬂammation that may
contribute to the increased risk for adverse cardiovascular
clinical outcomes [3]. However, once coronary artery disease
(CAD) developed in obese patients, poor clinical outcomes
did not occur according to some reports [4—9].
Despite some data concerning the relationship between
body mass index (BMI) and CAD existing, the clinical effect
of BMI on outcomes after percutaneous coronary interven-
tion (PCI) in patients with ST-segment elevation myocardial
infarction (STEMI) is not well known. Furthermore, the avail-
able data are based on western populations, not on the
oriental population.
Thus, we intended to evaluate the clinical effect of BMI
on outcomes after PCI in Korean patients with STEMI using
the Korean Acute Myocardial Infarction Registry (KAMIR).
Materials and methods
Study design and sample
KAMIR is a Korean prospective, open, observational, multi-
center on-line registry investigating the risk factors of
mortality in acute myocardial infarction (AMI) and estab-
lishing the universal management for the prevention of
AMI with support of the Korean Circulation Society since
November 2005. A total of 41 hospitals, which were capa-
ble of primary PCI, participated. This study evaluated age,
sex, body mass index, initial symptoms, vital signs, Kil-
lip class, symptoms, onset time, ambulance arrival time,
ﬁrst medical contact time, transfer time from ﬁrst hospital
to the primary PCI centers, door to needle time, door-
to-balloon time, each risk factor, past regular medication,
co-morbidities, electrocardiographic locations of MI, initial
treatment strategy, drugs, angiographic ﬁndings, in-hospital
complications, medical therapy in hospital, 1-, 6-, and
12-month follow-up major adverse cardiac events (MACEs)
(cardiac death, re-infarction, re-PCI, coronary artery bypass
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tology. Published by Elsevier Ireland Ltd. All rights reserved.
raft), and so on. We used KAMIR to deﬁne a cohort of
atients with AMI. The study protocol was approved by the
thics committee at each participating institution. The diag-
osis of AMI was based on the triad of chest pain, ECG
hanges, and raised serum cardiac enzyme level. During
ur study period of November 2005 to November 2007,
824 STEMI patients who arrived at hospital within 12 h
fter onset of chest pain and underwent primary PCI were
egistered in KAMIR. For this analysis, patients were clas-
iﬁed into four groups based on the suggestion by the
orld Health Organization for the Asian population [10]:
nderweight (Group I: BMI < 18.5 kg/m2, n = 129); normal
eight (Group II: 18.5≤BMI < 23.0 kg/m2, n = 1253); over-
eight (Group III: 23.0≤BMI < 27.5 kg/m2, n = 1959); and
bese (Group IV: BMI≥ 27.5 kg/m2, n = 483). Patients’ char-
cteristics consisted of medical history (diabetes mellitus,
ypertension, smoking, hyperlipidemia, previous AMI, previ-
us angina, previous coronary artery bypass graft, previous
CI, and family history); presentation characteristics (sys-
olic blood pressure and heart rate, symptom-to-door time,
oor-to-balloon time, and left ventricular ejection fraction,
hich was obtained within 24 h after admission in most
ases); the laboratory ﬁndings (glucose, creatinine, car-
iac enzymes, serum cholesterol, high-sensitivity C-reactive
rotein, and N-terminal pro-brain natriuretic peptide); and
he medical treatment; and angiographic and procedural
ndings. In-hospital mortality, MACEs, including in-hospital
ortality, revascularization, mortality in 1, 6, 12 months,
nd overall mortality were compared among the four groups.
tatistical analysis
tatistical analysis was performed using SPSS software, ver-
ion 15.0 (SPSS-PC Inc., Chicago, IL, USA). All continuous
ariables are reported as mean value± standard deviationharacteristics among groups. Survival analysis after AMI
as estimated using the Kaplan—Meier method with log-
ank tests to compare survival among groups. Univariate
nd multivariate analysis were done to identify the prognos-
ic factors affecting results. We used Chi-square tests and
8i
a
c
n
R
B
B
i
y
I
a
7
i
I
1
i
p
1
s
t
l
I
p
I
1
s
7
h
2
L
T
O
t
1
1
t
1
1
u
(
I
p
l
p6
ndependent-samples t-tests to ﬁnd the predictors for over-
ll mortality and used logistic regression analysis to adjust
onfounding factors. A p-value < 0.05 was considered as sig-
iﬁcant.
esults
aseline characteristics
aseline characteristics of the patient groups are listed
n Table 1. Overweight and obese group were signiﬁcantly
ounger (Group I: 69.7± 12.7 years, II: 64.7± 12.2 years,
II: 59.4± 11.9 years, and IV: 56.5± 12.5 years, p < 0.001)
nd more likely to be male patients (Group I: 62.8%, II:
0.9%, III: 79.5%, and IV: 76.4%, p = 0.009) with higher
ncidences of hypertension (Group I: 33.3%, II: 39.9%,
II: 47.2%, and IV: 54.2%, p < 0.001), diabetes (Group I:
7.3%, II: 22.5%, III: 23.5%, and IV: 28.7%, p = 0.005), smok-
ng (Group I: 58.9%, II: 60.3%, III: 64.2%, and IV: 66.2%,
= 0.006), and hyperlipidemia (Group I: 9.8%, II: 7.0%, III:
0.4%, and IV: 12.7%, p = 0.001). There were no signiﬁcant
tatistical differences in symptom-to-door time and door-
o-balloon time (p > 0.05). Underweight patients had lower
eft ventricular ejection fraction (Group I: 48.3± 14.0%,
I: 50.3± 11.7%, III: 51.3± 11.3%, and IV: 52.6± 11.6%,
< 0.001), lower systolic (Group I: 117.9± 33.6mmHg,
I: 122.6± 38.7mmHg, III: 125.8± 30.1mmHg, and IV:
M
A
I
Table 1 Baseline clinical characteristics.
Group I (N = 129) Group II (N = 12
Age (years)* 69.7± 12.7 64.7± 12.2
Female, n (%)* 48 (37.2) 365 (29.1)
CPR prior on arrival, n (%) 5 (3.9) 42 (3.4)
Typical pain, n (%)* 107 (84.9) 1095 (88.9)
SBP (mmHg)* 117.9± 33.6 122.6± 38.7
DBP (mmHg)* 71.7± 19.8 75.7± 31.9
SDT (min) 195.2± 131.3 189.9± 136.4
DBT (min) 105.6± 78.7 100.4± 73.9
LVEF (%)* 48.3± 14.0 50.3± 11.7
Killip≥ II, n (%)* 35 (28.7) 307 (25.4)
Anterior ECG, n (%)* 66 (54.1) 641 (54.4)
Inferior ECG, n (%)* 55 (45.1) 550 (46.7)
AF, n (%) 3 (2.4) 55 (4.5)
Risk factors, n (%)
Hypertension* 42 (33.3) 492 (39.9)
Diabetes mellitus* 22 (17.3) 278 (22.5)
Smoking* 76 (58.9) 748 (60.3)
Hyperlipidemia* 11 (9.8) 76 (7.0)
Previous AMI, n (%) 6 (4.7) 33 (2.7)
Previous angina, n (%) 5 (3.9) 48 (3.9)
Previous CABG, n (%) 0 (0) 9 (0.7)
Previous PCI, n (%) 4 (3.1) 53 (4.3)
Family history, n (%) 7 (6.1) 70 (6.4)
CPR: cardiopulmonary resuscitation; SBP: systolic blood pressure; DBP:
to-balloon time; LVEF: left ventricular ejection fraction; ECG: electroca
CABG: coronary arterial bypass graft; PCI: percutaneous coronary inter
* Signiﬁcance is p < 0.05.W.Y. Kang et al.
29.1± 30.8mmHg, p < 0.001) and diastolic blood pres-
ure (Group I: 71.7± 19.8mmHg, II: 75.7± 31.9mmHg, III:
8.7± 24.8mmHg, and IV: 80.6± 18.3mmHg, p < 0.001) and
igher rate of Killip class 1 (Group I: 28.7%, II: 25.4%, III:
2.4%, and IV: 22.5%, p = 0.001) (Table 1).
aboratory ﬁndings
able 2 shows results of the laboratory examination.
verweight and obese patients had higher levels of
otal cholesterol (Group I: 163.9± 50.2mg/dL, II:
75.4± 42.8mg/dL, III: 185.3± 42.7mg/dL, and IV:
91.7± 44.6mg/dL, p < 0.001) and low-density lipopro-
ein cholesterol (Group I: 101.9± 42.5mg/dL, II:
11.3± 36.6mg/dL, III: 120.4± 44.7mg/dL, and IV:
24.2± 53.1mg/dL, p < 0.001). N-terminal pro-brain natri-
retic peptide became signiﬁcantly lower, as BMI increased
Group I: 3991.1± 7436.2 pg/mL, II: 1863.3± 4854.7 pg/mL,
II: 1194.5± 3661.2 pg/mL, and IV: 845.9± 2901.5 pg/mL,
< 0.001). Also, there were no clinical differences in the
evels of glucose, creatinine, and high-sensitivity C-reactive
rotein between groups.edical treatment parameters
t admission, we used -blockers (Group I: 57.0%, II: 72.0%,
II: 75.4%, and IV: 78.9%, p < 0.001) and statins (Group I:
53) Group III (N = 1959) Group IV (N = 483) p-Value
59.4± 11.9 56.5± 12.5 <0.001
401 (20.5) 114 (23.6) <0.001
54 (2.8) 11 (2.3) 0.147
1786 (92.1) 447 (93.3) <0.001
125.8± 30.1 129.1± 30.8 <0.001
78.7± 24.8 80.6± 18.3 <0.001
179.3± 132.3 183.4± 134.1 0.115
101.9± 78.9 97.0± 65.1 0.578
51.3± 11.3 52.6± 11.6 <0.001
421 (22.4) 104 (22.5) 0.035
968 (52.0) 220 (47.4) 0.015
903 (48.5) 242 (52.2) 0.041
53 (2.8) 23 (4.9) 0.806
914 (47.2) 257 (54.2) <0.001
454 (23.5) 135 (28.7) 0.005
1250 (64.2) 317 (66.2) 0.006
179 (10.4) 52 (12.7) 0.001
64 (3.3) 15 (3.1) 0.825
78 (4.0) 15 (3.1) 0.657
2 (0.1) 2 (0.4) 0.175
89 (4.6) 27 (5.6) 0.177
142 (8.0) 37 (8.6) 0.067
diastolic blood pressure; SDT: symptom-to-door time; DBT: door-
rdiogram; AF: atrial ﬁbrillation; AMI: acute myocardial infarction;
vention.
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Table 2 Laboratory ﬁndings.
Group I (N = 129) Group II (N = 1253) Group III (N = 1959) Group IV (N = 483) p-Value
Glucose (mg/dL) 164.7 ± 72.4 177.2 ± 79.7 177.0 ± 78.6 177.6 ± 72.7 0.380
Creatinine (mg/dL) 1.26 ± 1.48 1.16 ± 1.52 1.13 ± 0.86 1.18 ± 1.50 0.566
CK (U/L)* 2291.9 ± 3165.5 1871.9 ± 2224.2 2185.2 ± 2337.9 2146.4 ± 2374.7 0.003
CK-MB (U/L)* 247.4 ± 234.0 191.5 ± 206.5 231.1 ± 360.1 225.6 ± 293.4 0.003
TnI (ng/mL) 69.2 ± 83.2 70.1 ± 194.9 74.7 ± 256.4 55.5 ± 69.8 0.513
TC (mg/dL)* 163.9 ± 50.2 175.4 ± 42.8 185.3 ± 42.7 191.7 ± 44.6 <0.001
LDL-C (mg/dL)* 101.9 ± 42.5 111.3 ± 36.6 120.4 ± 44.7 124.2 ± 53.1 <0.001
HDL-C (mg/dL)* 47.8 ± 12.6 46.4 ± 24.6 44.2 ± 15.9 45.3 ± 35.7 0.048
hsCRP (mg/dL) 15.0 ± 56.0 15.7 ± 80.4 16.1 ± 85.4 12.1 ± 67.5 0.860
NT-proBNP (pg/mL)* 3991.1 ± 7436.2 1863.3 ± 4854.7 1194.5 ± 3661.2 845.9 ± 2901.5 <0.001
: low
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oCK: creatine kinase; TnI: troponin-I; TC: total cholesterol; LDL-C
cholesterol; hsCRP: high-sensitivity C-reactive protein; NT-proBNP
* Signiﬁcance is p < 0.05.
75.0%, II: 73.0%, III: 77.2%, and IV: 79.3%, p = 0.003) more
frequently for the overweight and obese patients. Vasopres-
sors (Group I: 34.4%, II: 20.9%, III: 17.4%, and IV: 14.0%,
p < 0.001) and diuretics (Group I: 35.9%, II: 28.4%, III: 24.9%,
and IV: 25.1%, p = 0.005) were prescribed more frequently in
the underweight group. Except for those medications, there
were no signiﬁcant differences between groups in the usage
of other medications (Table 3).
Coronary angiogram and PCI
In underweight group, there was a higher incidence of left
main complex lesion (Group I: 2.4%, II: 1.8%, III: 1.5%, and IV:
0.2%, p = 0.017) and left anterior descending coronary artery
for the target vessel (Group I: 54.0%, II: 50.4%, III: 49.5%, and
IV: 43.5%, p = 0.015). The higher BMI, the bigger stent (Group
I: 3.11± 0.4mm, II: 3.18± 0.4mm, III: 3.24± 0.4mm, and
IV: 3.28± 0.5mm, p < 0.001) was used and the lower events
of complication (Group I: 26.8%, II: 18.0%, III: 16.2%, and IV:
15.3%, p = 0.007) occurred. Despite the use of drug-eluting
stents in most cases, there was a trend to use bare metal
stents in the underweight group (Table 4).
K
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Table 3 Prescribed medications.
Medications (%) Group I (N = 129) Group II (N
Aspirin 99.2 99.3
Clopidogrel 99.2 98.3
Cilostazole 39.1 37.4
Nitrate 69.5 65.1
Unfractionated heparin 60.9 58.2
Low molecular weight heparin 37.5 33.4
-Blocker* 57.0 72.0
Calcium channel blocker 9.4 7.3
Angiotensin-converting enzyme
inhibitor*
71.1 70.7
Angiotensin receptor blocker 13.3 12.2
Vasopressors* 34.4 20.9
Diuretics* 35.9 28.4
Statins* 75.0 73.0
* Signiﬁcance is p < 0.05.-density lipoprotein cholesterol; HDL-C: high-density lipoprotein
erminal pro-brain natriuretic peptide.
ajor adverse cardiac events and all-cause
ortality
able 5 demonstrates in-hospital outcomes and MACEs at 1,
, and 12 months for each of the patient groups. Obese
atients had signiﬁcantly lower mortalities (in-hospital
ortality: 7.9% in Group I, 4.4% in II, 3.0% in III, and
.7% in Group IV, p < 0.001; mortality at 1-year: 15.4% in
roup I, 3.3% in II, 2.6% in III, and 1.1% in Group IV,
< 0.001; overall mortality: 17.3% in Group I, 6.1% in II,
.5% in III, and 2.3% in Group IV, p < 0.001). MACEs showed
somewhat bimodal pattern (underweight: 28.2%, nor-
al weight: 15.2%, overweight: 13.0%, and obese: 14.8%,
= 0.031).
urvival curves and multivariate analysis for
verall mortalityaplan—Meier survival curves for mortality showed signiﬁ-
antly higher mortality in underweight patients (Fig. 1). In
he multivariate regression analysis, we found that no use of
tatins, old age, higher Killip class, and lower left ventricu-
= 1253) Group III (N = 1959) Group IV (N = 483) p-Value
99.2 98.7 0.399
98.9 98.1 0.954
35.1 33.9 0.082
69.3 68.6 0.109
60.7 62.3 0.139
31.9 36.4 0.939
75.4 78.9 <0.001
9.1 10.3 0.62
72.1 76.2 0.046
13.0 12.3 0.839
17.4 14.0 <0.001
24.9 25.1 0.005
77.2 79.3 0.003
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Table 4 Coronary angiogram and percutaneous intervention.
Group I (N = 129) Group II (N = 1253) Group III (N = 1959) Group IV (N = 483) p-Value
Lesion characteristics
Left main complex (%)* 2.4 1.8 1.5 0.2 0.017
Left main simple (%) 0 0.2 0.3 0.2 0.847
Three-vessel disease (%) 26.2 21.0 19.3 21.1 0.270
Two-vessel disease (%) 27.0 28.1 29.7 29.0 0.429
One-vessel disease (%) 44.4 48.8 49.3 49.5 0.472
Target vessel
Left main (%) 0.8 1.3 1.0 0.4 0.185
LAD (%)* 54.0 50.4 49.5 43.5 0.015
LCX (%) 9.5 9.6 10.2 11.8 0.229
RCA (%)* 35.7 38.7 39.3 44.3 0.043
ACC/AHA lesion classiﬁcation
Type A (%) 6.8 3.1 3.7 3.6 0.812
Type B1 (%) 11.9 16.5 16.3 19.7 0.096
Type B2 (%) 24.6 27.7 26.3 25.6 0.524
Type C (%) 56.8 52.7 53.7 51.0 0.557
Pre-PCI TIMI
TIMI 0 (%) 61.5 60.7 63.7 65.0 0.067
TIMI I (%) 7.4 10.7 9.8 8.9 0.535
TIMI II (%) 12.3 14.7 13.2 12.2 0.245
TIMI III (%) 18.9 13.9 13.3 13.9 0.380
Post-PCI TIMI
TIMI 0 (%) 0 0.7 0.9 0.9 0.318
TIMI I (%) 1.6 0.7 1.0 0.2 0.465
TIMI II (%) 3.3 4.6 4.1 6.6 0.176
TIMI III (%) 95.1 94.0 93.9 92.3 0.207
Drug-eluting stent (%) 94.8 92.4 90.1 91.3 0.071
Stent size (mm) 25.4± 5.9 24.9± 6.2 25.1± 6.4 25.0± 5.8 0.811
Stent diameter (mm)* 3.11± 0.4 3.18± 0.4 3.24± 0.4 3.28± 0.5 <0.001
Stent number 1.44± 0.8 1.39± 0.7 1.40± 0.7 1.38± 0.7 0.824
Success rate (%) 98.4 97.4 97.7 98.5 0.336
Complication rate (%)* 26.8 18.0 16.2 15.3 0.007
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* Signiﬁcance is p < 0.05.
ar ejection fraction were independent predictors of overall
ortality (Table 6).
iscussion
ur data revealed that overweight and obese patients
ad worse baseline characteristics, including hyperten-
ion, diabetes, smoking, and hyperlipidemia. Conversely,
nderweight patients had poor proﬁles associated with
emodynamic instability, including older age, lower blood
ressure, higher Killip class, and lower left ventricular ejec-
ion fraction. Our clinical follow-up results showed that
bese and overweight patients had better short- and long-
erm prognosis than underweight patients.
Not only are overweight and obesity associated with
ncreased risk of developing cardiovascular disease [1,2],
ut also obesity is associated with endothelial dysfunction,
nsulin resistance, and inﬂammation that may contribute
b
p
w
t
aoronary artery; RCA: right coronary artery; ACC/AHA: American
oronary intervention; TIMI: thrombolysis in myocardial infarction.
o an increased risk for adverse clinical outcomes [3]. So,
e initially hypothesized that the obese and overweight
atients who received primary PCI in STEMI would have poor
rognosis compared with counterparts, despite some data
upporting the obesity paradox in coronary artery disease
4—9].
What made these results? Our analysis showed that
ncreased body mass index is associated with greater
se of guideline-recommended therapies on admission. -
lockers, angiotensin-converting enzyme inhibitors, and
tatins were prescribed more frequently for overweight and
bese patients. As shown in Table 6, statins provide an inde-
endent protective effect in overall mortality. This trend
as consistent with a previous report advocated by Stein-
erg et al. [11]. They concluded that overweight and obese
atients with acute myocardial infarction or unstable angina
ere more likely to receive aspirin, -blockers, inhibitors of
he rennin—angiotensin system, and lipid-lowering agents,
nd that they also were more likely to undergo cardiac
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Table 5 In-hospital, mid-term, and long-term outcomes.
Group I (N = 129) Group II (N = 1253) Group III (N = 1959) Group IV (N = 483) p-Value
CCU stay days (%)* 4.6± 5.6 3.4± 4.4 3.3± 3.9 3.1± 5.4 0.014
In-hospital mortality (%)* 7.9 4.4 3.0 1.7 <0.001
1-Month follow-up Group I (N = 107) Group II (N = 1058) Group III (N = 1657) Group IV (N = 415) p-Value
MACE (%) 4.0 2.3 1.9 3.5 0.844
All-cause mortality (%) 2.0 1.2 1.0 0.2 0.085
Cardiac death (%)* 2.0 1.0 0.5 0.2 0.022
Non-cardiac death (%) 0 0.2 0.5 0 0.781
Myocardial infarction 1.0 0.2 0.1 0.2 0.418
Revascularization (%)
CABG (%) 0 0.1 0 0.2 0.604
Re-PCI (%) 1.0 0.9 0.8 2.7 0.032
TLR (%) 1.0 0.2 0.4 0.2 0.870
TVR (%) 0 0 0 0
Non-TVR (%)* 0 0.6 0.4 2.5 0.003
6-Month follow-up Group I (N = 86) Group II (N = 865) Group III (N = 1344) Group IV (N = 341) p-Value
MACE (%) 20.7 8.2 8.4 10.3 0.401
All-cause mortality (%)* 10.3 2.0 1.6 0.9 <0.001
Cardiac death (%)* 5.7 1.6 1.0 0.6 0.002
Non-cardiac death (%) 4.6 0.4 0.7 0.3 0.062
Myocardial infarction 1.1 0.6 0.3 0.6 0.460
Revascularization (%)
CABG (%) 0 0.2 0.1 0.3 0.844
Re-PCI (%) 9.2 5.5 6.4 8.5 0.237
TLR (%) 2.3 2.1 2.4 2.4 0.745
TVR (%) 1.1 0.5 0.8 0.9 0.523
Non-TVR (%) 5.7 2.8 3.1 5.0 0.354
12-Month follow-up Group I (N = 69) Group II (N = 648) Group III (N = 1041) Group IV (N = 255) p-Value
MACE (%)* 28.2 15.2 13.0 14.8 0.031
All-cause mortality (%)* 15.4 3.3 2.6 1.1 <0.001
Cardiac death (%)* 9.0 2.6 1.5 0.8 <0.001
Non-cardiac death (%)* 7.7 0.8 1.1 0.4 0.007
Myocardial infarction 2.6 1.1 0.5 1.1 0.246
Revascularization (%)
CABG (%) 0 0.5 0.4 0.4 0.946
Re-PCI (%) 11.5 10.8 9.6 12.1 0.985
TLR (%) 2.6 4.6 3.3 3.8 0.584
TVR (%) 1.3 1.2 1.3 1.1 0.989
Non-TVR (%) 7.7 5.0 4.9 6.8 0.773
Overall mortality (%)* 17.3 6.1 4.5 2.3 <0.001
CCU: coronary care unit; MACE: major adverse cardiac event; CABG: coronary artery bypass graft; PCI: percutaneous coronary interven-
tion; TLR: target lesion revascularization; TVR: target vessel revascularization.
* Signiﬁcance is p < 0.05.
Table 6 Multivariate analysis for overall mortality.
Odds ratio 95% CI p-Value
Use of statins 0.346 0.133—0.896 0.029
Old age 1.094 1.036—1.155 0.001
High Killip class 1.599 1.002—2.559 0.049
High left ventricular ejection fraction 0.946 0.899—0.995 0.031
High body mass index 1.040 0.905—1.195 0.583
Signiﬁcance is p < 0.05*.
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Figure 1 Kaplan—Meier survival curves for the four groups.
Survival curve analysis reveals a signiﬁcantly higher mortality
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Kate in Group I than the other groups (Group I: underweight;
roup II: normal weight; Group III: overweight; Group IV:
bese).
atheterization, PCI, and coronary artery bypass graft.
ecause obese and overweight patients have more tradi-
ional risk factors for CAD and are expected to better
olerate aggressive management, medical teams give more
uideline-recommended therapies on admission [12—15]. As
roven in previous studies, there is a link between inva-
ive management of acute coronary syndrome and use of
roved, evidence-based treatments [16,17]. This is why we
rst thought that the most important reason why overweight
nd obese patients with STEMI undergoing PCI had good out-
omes.
In addition, overweight and obese patients had higher
lood pressure, lower Killip class, and higher left ventricu-
ar ejection fraction compared with underweight patients,
ndicating they were relatively in a more hemodynamically
table state. Our multivariate analysis showed hemodynamic
nstability, including lower left ventricular ejection frac-
ion and higher Killip class are independent predictors of
verall mortality. Underweight patients, in whom there was
emodynamic instability, had a trend of less frequent use
f -blockers and angiotensin-converting enzyme inhibitors,
nd more frequent use of vasopressors and diuretics. Also,
e could ﬁnd the hemodynamic state in laboratory ﬁndings.
erum N-terminal pro-brain natriuretic peptide level was
igniﬁcantly lower in overweight and obese patients. The
evel of N-terminal pro-brain natriuretic peptide, an indica-
or of the hemodynamic severity of MI and left ventricular
ysfunction, is considered one of the most powerful pre-
ictors of death in AMI [18—20]. Therefore, overweight and
bese patients who were in a hemodynamically stable state
ompared with underweight and normal weight patients may
ave favorable outcomes according to the present study.
In the present study, elderly patients were more fre-
uently in the underweight and normal weight groups.
revious reports revealed that elderly patients had worse
utcomes after AMI regardless of treatment [21,22]. Our
ultivariate analysis demonstrated that age is an inde-
endent risk factor for overall mortality. This result was
N
M
M
M
GW.Y. Kang et al.
onsistent with previous studies. Physicians had a tendency
f more aggressive use of medications for younger patients
hat may inﬂuence a favorable effect on outcomes [23].
ecent studies demonstrated that younger age in obesity
ad a major impact on protection in AMI [24,25].
tudy limitations
lthough BMI has been considered as a marker of obesity,
t is a crude indicator of body adiposity, not a direct mea-
urement of body composition. So, it may not reﬂect the
ctual degree of body fat content. We did not deﬁne obesity
y other methods such as waist circumference, waist—hip
atio, or abdominal height. Also, we did not have the data
elated to the change in BMI or weight during the follow-up
eriod. Therefore, we could not determine the impact of
eight reduction on outcomes after primary PCI, especially
n overweight or obese patients.
KAMIR is an observational registry rather than a random-
zed trial. Therefore, our analysis has all the limitations of
etrospective analysis using prospectively collected data.
lso, the follow-up duration was relatively short. There-
ore we could not exclude the possibility that obesity may
nﬂuence the very long-term outcomes, because obesity may
ave a delayed effect on the progression of coronary artery
isease.
onclusion
besity is not an independent predictor of overall mor-
ality in patients with STEMI undergoing primary PCI.
owever, obese patients are associated with lower mor-
ality. These results can be explained by better use of
uideline-recommended medical treatment, hemodynamic
tability, and younger age. To identify the impact of obe-
ity on outcomes in patients undergoing primary PCI and to
lucidate the long-term effect, a well-designed prospective
tudy may be needed.
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